Laryngeal Inflammatory Myofibroblastic Tumor With Anemia and Thrombocytosis

Abstract

Inflammatory myofibroblastic tumor (IMT) of the larynx is a rare benign lesion that commonly occurs in the soft tissues. We present the first case with systemic manifestations of laryngeal IMT that was associated with hypochromic, microcytic-type anemia and thrombocytosis.

Larynx myofibroblastic tumor, a rare case report

“…A close clinical follow-up of this pathology is essential, with most series requiring it for at least 12 months, given the variable risk of recurrence and distant metastases. 8,12,15,16,19,20 F I G U R E 4 Fibrolaryngoscopic examination 6 months after surgery, with an area of nodular fibrotic appearance suspicious for recurrence in the area of surgical resection Given the marked inflammatory component of the lesion, a second-line corticosteroid therapy is widely validated in cases with contraindications for surgery or tumor recurrence, and it is also used for head and neck IMT in locations other than the larynx. 1 Genetic alterations are opening new lines of research: series of treatment with ALK inhibitor crizotinib have been published in cases of ALK-positive ITM, as a secondline therapy for those cases of contraindication to surgery, partial resection, or positive surgical margins.…”

“…Radiochemotherapy is reserved for cases with positive margins or a formal contraindication to surgery. A close clinical follow‐up of this pathology is essential, with most series requiring it for at least 12 months, given the variable risk of recurrence and distant metastases 8,12,15,16,19,20 …”

“…Locally, the inflammatory and expansive behavior of the lesion can cause great clinical variability, mimicking other neoplastic processes. Primary involvement at the laryngeal level with systemic symptoms including constitutional syndrome, fever, anemia, or thrombocytopenia has been described, 15 , 16 which reflects the variability and morbidity associated with this pathology. The definitive diagnosis is eminently anatomopathological.…”

“…A close clinical follow‐up of this pathology is essential, with most series requiring it for at least 12 months, given the variable risk of recurrence and distant metastases. 8 , 12 , 15 , 16 , 19 , 20 …”

Inflammatorischer myofibroblastischer Tumor in einer Kindernase

“…Obwohl es sich um einen benignen Tumor handelt, zeigt die klinische Erfahrung, dass eine hohe Rezidivrate besteht. Aus diesem Grund empfehlen Kaytez et al eine engmaschige klinische Nachsorge und im regelmäßigen Intervall eine MRT-Bildgebung [5]. Ergänzend sei bemerkt, dass es auch keine einheitliche Empfehlung für die Dauer der Nachsorge gibt.…”